First Subject Dosed in Biosplice Therapeutics Phase 1b Clinical Trial in Oncology

NEXT STORY
Recent Peer-Reviewed Publication Confirms Patient Satisfaction with Multiple Allergy Immunotherapy Options
PREV STORY
Novome Biotechnologies Reports Positive Results from a Phase 1 Study of NOV-001
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

SOLAR-1 trial of Novartis investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) meets primary endpoint in HR+/HER2- advanced breast cancer with PIK3CA mutation

SOLAR-1 evaluated BYL719 plus fulvestrant vs. fulvestrant alone in HR+/HER2- advanced breast cancer patients ...

author_avatar
NASDAQ Market News

The global biosimilars market is projected to reach USD 44.7 billion by 2026 from USD 15.6 billion in 2021, at a CAGR of 23.5% during the forecast period of 2021 to 2026

author_avatar
NASDAQ Market News

Targovax presents further positive clinical data from TG01 phase I/II trial at 2017 ASCO annual meeting

Oslo, Norway, 6 June 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a ...

author_avatar
NASDAQ Market News